PSY7 Estimating Quality of Life of Patients with Lipodystrophy  by Dhankhar, P. et al.
A292  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
cant. CONCLUSIONS: These findings suggest that algorithms based on medical and 
billing records can be used to identify patients with suspected HIT.
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OBJECTIVES: This systematic review and meta-analysis studied major surgical com-
plications, including pulmonary embolism (PE), myocardial infarction (MI), and leak, 
resulting from different bariatric surgery procedures, using recently published data 
and appropriate meta-analysis techniques. METHODS: Surgeries considered were 
Roux-en-Y gastric bypass (RYGB), adjustable gastric banding (AGB), and sleeve gas-
trectomy (SG). Literature searches of PubMed, Embase, Scopus, and the Cochrane 
Library databases between 2003 and September 2014 were performed. Articles were 
screened for exclusion and inclusion criteria before data extraction. Quality of evi-
dence was assessed and each article was rated for quality. Post-surgery complication 
rates of PE, MI, and leak were stratified by time points (≤ 30 day and > 30 day) and 
synthesized by Bayesian random-effects meta-analyses. In cases in which both 
randomized control trials (RCTs) and observational studies (OBSs) were available, 
RCTs and OBSs were analyzed separately. RESULTS: Our study included 61 articles 
(60 OBSs, 1 RCT) and 108,396 patients with a mean age of 44.3 years and mean 
pre-surgery body mass index (BMI) of 46.5 kg/m2. Only one article recorded a leak 
following RYGB at ≥ 30 days, reporting 2 in 218 patients. The ≤ 30 day mean rate of 
complications and the 95% credible intervals (in brackets) for OBSs are presented. 
The leak rate for RYGB was 0.91% [0.56%, 1.35%] and for SG was 0.72% [0.01%, 2.54%]. 
The MI rate for RYGB was 0.06% [0.02%, 0.15%] and higher for AGB 1.05% [0%, 2.68%]. 
Incidence of PE for all procedures was 0.35% [0.14%, 0.74%], with AGB having the 
lowest rate (0.11%), followed by SG (0.54%) and RYGB (0.69%). CONCLUSIONS: This 
study suggests that the risk of PE, MI, and leak following bariatric surgery is low. 
However, these are serious, life-threatening adverse events with non-negligible coin-
cidence whose risk should be effectively communicated to patients when surgical 
treatment is considered.
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OBJECTIVES: Lipodystrophy syndromes (LD-S) are rare syndromes characterized by 
selective loss of fat and severe metabolic abnormalities. Based on patient accounts, 
LD-S have a significant impact on quality of life (QOL). This is the initial organized 
effort to estimate the QOL for individuals with LD-S based on the patient’s self-
reported findings. METHODS: LD Connect, launched in January 2014, is a global 
registry for the lipodystrophy community, including patients and caregivers. This 
registry collects self reported data from members who join the effort on the regis-
try website (www.ldconnect.org). We analyzed QOL data collected from individuals 
who self-identified as having lipodystrophy through December 9, 2014. The QOL 
questionnaire included items from the Patient Reported Outcomes Measurement 
Information System (PROMIS) short forms, questions on financial impact and 
impact of pain. We estimated T-scores for the participants where a T-score of 50 
represents the average score for the general population with a standard devia-
tion (SD) of 10. EQ-5D scores were also estimated from PROMIS global health 
items. RESULTS: Out of 126 participants, 48% responded to the QOL questionnaire. 
Among responders 97% were females, 84% had partial LD, and 51% were from the 
US. T-scores for physical and mental health were 43.14 and 41.90 (SD 9.05 and 
9.38, respectively). T-scores for social isolation, social support, and stigma were 
51.57, 52.91, and 55.30, respectively. The estimated average EQ-5D score for LD-S 
was 0.67; much lower than the average EQ-5D of a general population (0.866). 
Patients also reported a minimal to moderate financial impact of lipodystrophy, 
with 27% reporting that costs affected their decision to seek care for lipodystro-
phy. CONCLUSIONS: LD-S patients reported having some impairment in quality 
of life on domains of physical health, and mental health, social isolation, and 
stigma compared to general population. Further work is required to characterize 
the extent of impairment.
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OBJECTIVES: To compare the disease status and outcomes of patients with AS 
receiving adalimumab and etanercept monotherapy in the US. METHODS: A 
medical chart-review of AS patients was conducted to collect de-identified data 
for those recently treated with a biologic as part of usual care. Physicians (rheu-
matologists) were screened for duration of practice (3-30yrs) and patient volume 
(incl. > 5 AS biologic patients/month) and recruited from a large panel to be geo-
graphically representative. Eligible patient charts (≥ 3) were randomly selected 
from a sample of patients visiting each center/practice during the screening 
period. Physicians abstracted patient diagnosis, treatment patterns/dynamics 
and patient symptomatology/disease status/outcomes. Patients on adalimumab/
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OBJECTIVES: Safety studies have shown that risks associated with use of non-
steroidal anti-inflammatory drugs (NSAIDs) are related to dose and release form; 
however, there is little US evidence. This study assessed the relationships between 
diclofenac dose and release form on gastrointestinal (GI), cardiovascular (CV), and 
renal events using US health care claims. METHODS: The MarketScan© Commercial 
Claims and Encounters database (2008-12) was used to analyze the risks of GI (upper 
GI bleed/perforation [UGIB], lower GI bleed [LGIB]), CV (myocardial infarction [MI], 
stroke, and congestive heart failure [CHF]), and renal events by diclofenac dose 
category relative to no current NSAID use and extended/delayed release (ER) rela-
tive to immediate release (IR) form among new adult users of diclofenac. Patients 
with prior history of GI, CV or renal disease were excluded. Hazard ratios (HRs) were 
estimated using multivariable Cox regression models with total daily dose (TDD) and 
release form as time-dependent covariates. RESULTS: In total, 851,549 diclofenac 
users (57% female; median age 50 years) met the initial study inclusion criteria. At 
diclofenac initiation, median TDD was 150mg (range: 1-400mg) and most (88.25%) 
prescriptions were ER. The HRs (95% CIs) for TDD > 150mg (vs no current exposure) 
were: UGIB: 3.48 (2.25-5.37) for ER and 2.59 (1.55-4.33) for IR; LGIB: 1.58 (1.31-1.91) 
for ER and 1.37 (1.11-1.70) for IR; MI: 1.10 (0.74-1.62) for ER and 1.02 (0.66-1.60) for IR; 
stroke: 1.08 (0.90-1.31) for ER and 1.09 (0.88-1.34 for IR); CHF: 1.39 (1.14-1.70) for ER 
and 1.38 (1.10-1.74) for IR; and renal failure: 2.25 (1.84-2.76) for ER and 2.05 (1.60-2.61) 
for IR. CONCLUSIONS: In an analysis of US health care claims, increased risks of 
certain adverse events were associated with higher doses compared with no cur-
rent use and with ER compared with IR form among new users of diclofenac with 
no prior history of the event.
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OBJECTIVES: Peginesatide is a peptide-based erythropoietin receptor agonist 
withdrawn after anaphylaxis/hypotension events (AHEs) occurred in 2012 and 
2013. Centers affiliated with a phase IV study conducted by the largest dialysis 
organization (LDO) in the United States treated 20,000 patients and unaffiliated 
centers treated 5,000 patients. Our objective was to summarize AHEs associated 
with peginesatide during the phase IV study. METHODS: The pilot included man-
ufacturer-supplied nurse monitors at 10 LDO sites who prospectively evaluated 
efficacy, safety, and logistics of peginesatide. Interim analyses in January 2013 were 
favorable. A protocol change in October required that no other intravenous medica-
tion be administered within one hour of peginesatide, after 8 anaphylaxis hypo-
tension events from the pilot occurred. The pilot was expanded to 348 of the LDO’s 
2100 sites. Centers unaffiliated with the pilot also provided peginesatide without 
monitoring. We compared timeliness, quantity, and characteristics of anaphylaxis-
hypotension events from each setting. RESULTS: Twenty eight AHEs were from the 
phase IV study (1.4 per 1,000 patients) and 10 were from unaffiliated centers (1.4 
per 1,000 patients). Centers in the pilot reported events more rapidly (median days 
= 46 versus 81). Minutes to onset was similar (median = 3 versus 5). AHEs from the 
pilot were more often grade 4 severity or fatal (44% versus 10%) or associated with 
cardiorespiratory arrest (29% versus 0%). On February 11 and 12, 2013, three fatalities 
and two grade IV events occurred at four pilot sites. An unplanned analysis identi-
fied a fatality rate of 0.3/1000-treated patients in the pilot study. Peginesatide was 
withdrawn. CONCLUSIONS: Absent timely and comprehensive conduct of the LDOs 
pilot study , the safety signal may have gone unnoticed for years. Prospectively-
monitored phase IV studies could enhance detection of rare serious adverse events 
of novel medicines, including biologicals.
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OBJECTIVES: The aim of this study was to develop and compare three algorithms for 
identifying heparin-induced thrombocytopenia (HIT) using gold standard measures 
of clinically suspected and actual HIT. METHODS: We identified 45,096 inpatients 
exposed to heparin from 2006 to 2011 at an urban academic medical center. Three 
algorithms were examined: (A) initiation of direct thrombin inhibitor (DTI) treat-
ment and a diagnostic test ordered more than 4 days after exposure to heparin; (B) 
algorithm A plus presence of ICD-9-CM code 287.4, 287.5, or 289.84; and (C) algorithm 
A plus presence of ICD-9-CM code 289.84. The data were collected from medical and 
billing records for patients (n= 39) identified by algorithm A and a random sample 
(n= 250) of patients who did not meet the algorithm’s definition. Algorithms B (n= 24) 
and C (n= 6) were subsets of algorithm A. The performance of the algorithms was 
computed based on the ascertainment of confirmed/suspected HIT by clinicians. 
Suspected HIT cases were tested for HIT antibodies and administered DTI to treat 
HIT. RESULTS: The positive predictive values (PPV) for confirmed HIT were 30.77%, 
37.50% and 50% for algorithms A, B and C, respectively (P= 0.547). However, the PPV 
was 100% for suspected HIT for all three algorithms. The differences in sensitivity 
between the algorithms A, B, and C for confirmed (100% vs. 75% vs. 50%; P= 0.024) 
and suspected (100% vs. 61.54% vs. 40%; P< 0.001) HIT were statistically signifi-
